吸烟状态与接受前列腺癌根治术或放疗的局限性前列腺癌患者复发、转移及死亡风险的关联:系统综述与荟萃分析
结果显示,当前吸烟者生化复发(HR 1.40)、转移(HR 2.51)和癌症特异性死亡(HR 1.89)风险均显著升高;既往吸烟者仅生化复发风险轻度升高(HR 1.19),转移和癌症特异性死亡风险无显著增加。
要点
- 当前吸烟者接受根治性治疗后生化复发风险显著增加(HR 1.40)。
- 当前吸烟者转移风险(HR 2.51)和癌症特异性死亡风险(HR 1.89)显著升高。
- 既往吸烟者仅生化复发风险轻度升高,转移和死亡风险无显著增加。
核心结论
- 当前吸烟的局限性前列腺癌患者在接受根治性治疗后,生化复发、转移及癌症特异性死亡风险均显著高于非吸烟者。
研究设计与样本
- 系统综述与荟萃分析,检索2000年1月至2017年3月PubMed、MEDLINE、Embase和Cochrane Library数据库。
主要发现
- 当前吸烟者生化复发风险显著升高(HR 1.40,95% CI 1.18-1.66,P < .001,10项研究)。
- 既往吸烟者生化复发风险亦显著升高(HR 1.19,95% CI 1.09-1.30,P < .001,7项研究)。
- 当前吸烟者转移风险显著升高(HR 2.51,95% CI 1.80-3.51,P < .001,3项研究)。
- 当前吸烟者癌症特异性死亡风险显著升高(HR 1.89,95% CI 1.37-2.60,P < .001,5项研究)。
- 既往吸烟者转移风险(HR 1.61,95% CI 0.65-3.97,P = .31,2项研究)和癌症特异性死亡风险(HR 1.05,95% CI 0.81-1.37,P = .70,4项研究)无显著增加。
临床怎么用
- 应告知当前吸烟的局限性前列腺癌患者,其根治性治疗后复发、转移和死亡风险较高。
- 鼓励患者戒烟,并可将吸烟状态纳入预后评估和随访管理。
局限性
- 纳入研究均为观察性非随机研究,存在固有偏倚风险。
- 部分结局(如转移和癌症特异性死亡)的定量分析研究数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies investigating the association of cigarette smoking with prostate cancer incidence and outcomes have revealed controversial results. OBJECTIVE: To systematically review and analyze the association of smoking status with biochemical recurrence, metastasis, and cancer-specific mortality among patients with localized prostate cancer undergoing primary radical prostatectomy or radiotherapy. DATA SOURCES: A systematic search of original articles published between January 2000 and March 2017 was performed using PubMed, MEDLINE, Embase, and Cochrane Library databases in March 2017. STUDY SELECTION: Observational studies reporting Cox proportional hazards regression or logistic regression analyses were independently screened. DATA EXTRACTION AND SYNTHESIS: This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions. Available multivariable hazard ratios (HRs) and corresponding 95% CIs were included in quantitative analysis. A risk-of-bias assessment was completed for nonrandomized studies. MAIN OUTCOMES AND MEASURES: Prespecified outcomes of interest were biochemical recurrence, metastasis, and cancer-specific mortality. RESULTS: A total of 5157 reports were identified, of which 16 articles were selected for qualitative analysis and 11 articles were selected for quantitative analysis. All included studies were observational and nonrandomized and comprised a total of 22 549 patients. Overall, 4202 patients (18.6%) were current smokers. The overall median follow-up was 72 months. Current smokers had a statistically significantly higher risk of biochemical recurrence (HR, 1.40; 95% CI, 1.18-1.66; P < .001 [10 studies]), as did former smokers (HR, 1.19; 95% CI, 1.09-1.30; P < .001 [7 studies]). Current smokers were also at a higher risk of metastasis (HR, 2.51; 95% CI, 1.80-3.51; P < .001 [3 studies]) and cancer-specific mortality (HR, 1.89; 95% CI, 1.37-2.60; P < .001 [5 studies]), whereas former smokers were not (metastasis: HR, 1.61; 95% CI, 0.65-3.97; P = .31 [2 studies]; cancer-specific mortality: HR, 1.05; 95% CI, 0.81-1.37; P = .70 [4 studies]). CONCLUSIONS AND RELEVANCE: Current smokers at the time of primary curative treatment for localized prostate cancer are at higher risk of experiencing biochemical recurrence, metastasis, and cancer-specific mortality.
引用
- Foerster B, Pozo C, Abufaraj M, et al. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. JAMA Oncol. 2018. PMID: 29800115. doi:10.1001/jamaoncol.2018.1071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。